Pay in 4 interest-free payments of $7.35 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Seven additional Phase 3 readouts expected through 2026: TRIUMPH-1 (obesity), TRIUMPH-2 (obesity + diabetes), TRIUMPH-3 (obesity + cardiovascular risk), SELECT-M (MASH), SLEEP (OSA), BACK PAIN, and a cardiovascular/renal outcomes readout
amycretin has no CV data Conclusion# Amycretin represents the most exciting pipeline asset in obesity medicine, with 24.3% weight loss in early trials suggesting it could substantially exceed every approved treatment
Topiramate XR (50 mg) : Approximately $10 per month
10.3389/fimmu.2017.00093 237 Ron-HarelN.GhergurovichJ
US$ 26.25
US$ 22.01
US$ 22.72
